Experts’ consensus on the management and treatment of individuals with X-linked hypophosphatemia across lifespan

Individuals with XLH often experience unmet needs throughout life; a multidisciplinary approach involving different specialists, is recommended. The new treatment with burosumab can provide an effective and safety therapeutic option in reducing the burden of the disease in both children and adults. Therefore, awareness about the XLH disease should be increased among stakeholders. The criteria and reimbursement policies of burosumab should be revised.

Authors

Institutions

Publication Details

Journal
Journal of Endocrinological Investigation
Published
2025-07-01
DOI
https://doi.org/10.1007/s40618-025-02611-7
Citations
1
Primary Topic
Parathyroid Disorders and Treatments
Type
article
Field-Weighted Citation Impact
1.43

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Experts’ consensus on the management and treatment of individuals with X-linked hypophosphatemia across lifespan

M. Barale, Giorgia Grassi, Giampiero I. Baroncelli, Natascia Di Iorgi et al.
1 citations
Journal of Endocrinological Investigation
Parathyroid Disorders and Treatments
1.43
article

Experts’ consensus on the management and treatment of individuals with X-linked hypophosphatemia across lifespan

M. Barale, Giorgia Grassi, Giampiero I. Baroncelli, Natascia Di Iorgi, Stefano Mora, Pasquale Comberiati, Stefano Stagi, Laura Gianotti, Barbara Ruggiero, Sabrina Corbetta, Danilo Fintini, Giuseppe Vezzoli, Francesco Emma, Maria Luisa Brandi, Filomena Cetani, Valentina Camozzi, Anna Grandone, Andrea Palermo, Sandro Giannini, Rosaria Maddalena Ruggeri, Pitea Marco, Francesca Pigliaru, Cristina Eller-Vainicher, Vincenzo Rochira, Elena Castellano, Carrara Silvia, Procopio Massimo, Manuela Caruso Nicoletti
article en
1 citations

Abstract

Individuals with XLH often experience unmet needs throughout life; a multidisciplinary approach involving different specialists, is recommended. The new treatment with burosumab can provide an effective and safety therapeutic option in reducing the burden of the disease in both children and adults. Therefore, awareness about the XLH disease should be increased among stakeholders. The criteria and reimbursement policies of burosumab should be revised.

Journal of Endocrinological InvestigationVol. 48(10)
University of Pisa (IT), University of Messina (IT), University of Modena and Reggio Emilia (IT), University of Padua (IT), Vita-Salute San Raffaele University (IT), University of Cagliari (IT), University of Milan (IT), University of Campania "Luigi Vanvitelli" (IT), Istituto Giannina Gaslini (IT), Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT), University of Catania (IT), Azienda Ospedaliero-Universitaria di Modena (IT), Meyer Children's Hospital (IT), Bambino Gesù Children's Hospital (IT), IRCCS Ospedale San Raffaele (IT), IRCCS Istituto Auxologico Italiano (IT), Associazione Italiana Vulvodinia Onlus (IT), Azienda Sanitaria Ospedaliera S.Croce e Carle Cuneo (IT), Azienda Ospedaliera Universitaria Policlinico "G. Martino" (IT), Campus Bio Medico University Hospital (IT), Istituti di Ricovero e Cura a Carattere Scientifico (IT), Azienda Ospedaliera Universitaria Pisana (IT), University of Florence (IT), University of Turin (IT), University of Genoa (IT)
Ministero della Salute, European Rare Kidney Disease Reference Network
Zero hunger
Openalex Percentile: Top 18%
Parathyroid Disorders and Treatments
1.43
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.